Viotika Life Sciences Inc. was incorporated in 2018 to accelerate the promising research and explore the commercial potential of the VIO platform as a solution for the global antimicrobial resistance (AMR) crisis.
The VIO platform of drugs targets NQR, a protein that is present in over 100 pathogenic bacterial species found in humans, mammals, and fish. It is a novel lens through which to address AMR and it comes at a critical time as conventional antibiotics are becoming increasingly ineffective against infections. Learn more about our science.
While the company was established in 2018, Chief Scientific Officer Dr. Grant Pierce, Chief Scientific Advisor Dr. Pavel Dibrov, and their colleagues started their academic collaboration in 2008. The science behind their approach took root in 2001.
Viotika Life Sciences Inc. is based in Winnipeg, Manitoba, Canada. The company holds patents in the United States and Australia. Patents are pending in Canada, China, Europe, India, Israel, and Japan.
The company’s current valuation is CAD 20 million. Inquiries from interested investors are welcome.
CONTACT USQuotation Request
OUR TEAMWe'll Ensure You Always Get the Best Results
Regardless of which division, testing services, silicone mock vessels, or test equipment, our team will go above and beyond to ensure the highest level of service and accuracy of data.
Dr. Richard Garrett
CHIEF MEDICAL LABORATORY SCIENTIST (CMLS)
PRINCIPAL INVESTIGATORNicholas King, PhD
LABORATORY TECHNICIANLinda Hoffman, PhD
LABORATORY MANAGERMelissa Williamson, PhD
TESTIMONIALSWhat Our Clients Say
I greatly appreciate the communication on the process, what we needed to do in terms of providing samples, what to expect. Novalab provided what we needed in terms of certification that we can use with our customers.
Morgan Macleod
MEDICMETRIKA
MEDICMETRIKA